Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.81
+0.44005.26%
Pre-market: 8.870.0600+0.68%06:30 EDT
Volume:2.91M
Turnover:25.85M
Market Cap:512.20M
PE:-3.57
High:9.24
Open:9.11
Low:8.71
Close:8.37
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.12
T/O Rate:6.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.08
PE(LYR):-3.90

Loading ...

Capricor Therapeutics Inc : Piper Sandler Cuts to Neutral from Overweight; Cuts Target Price to $2 from $58

THOMSON REUTERS
·
Jul 30

FDA panel votes 9-3 against Capricor’s deramiocel

TIPRANKS
·
Jul 30

Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30

Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

Simply Wall St.
·
Jul 29

Capricor Therapeutics announces publication of HOPE-3 data on deramiocel

TIPRANKS
·
Jul 29

Capricor Says Phase 3 Hope-3 Trial Shows Deramiocel Slows Upper Limb Decline 54% in Duchenne Muscular Dystrophy

Reuters
·
Jul 29

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

GlobeNewswire
·
Jul 29

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Jul 29

Capricor Therapeutics Shares Fall After B. Riley, Roth Capital Downgrades

MT Newswires Live
·
Jul 29

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63

MT Newswires Live
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Thermo Fisher (TMO)

TIPRANKS
·
Jul 28

Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital

TIPRANKS
·
Jul 28

Capricor Therapeutics Down over 63%, on Pace for Largest Percent Decrease Since February 2007

Dow Jones
·
Jul 28

Capricor Publishes Advisory Committee Presentation on Deramiocel Clinical Data in Duchenne Muscular Dystrophy

Reuters
·
Jul 27

Capricor Disputes FDA Post-hoc Analyses of Deramiocel Data Ahead of July 29 Advisory Panel

Reuters
·
Jul 27

Capricor Therapeutics Shares Slide on Negative FDA Comments

Dow Jones
·
Jul 27

Capricor Therapeutics plunges after FDA posts deramiocel briefing notes

TIPRANKS
·
Jul 27

Oppenheimer would own Capricor Therapeutics into committee meeting

TIPRANKS
·
Jul 27

B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Jul 27